A case of fugitive acromegaly, initially presented as invasive prolactinoma

Endocrine

Volumn 38, Issue 1, 2010, Pages 1-5

  Lim, Jung Soo ^a,b   Ku, Cheol Ryong ^a,b   Lee, Mi Kyung ^c   Kim, Tai Seung ^a   Kim, Sun Ho ^b   Lee, Eun Jig ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Dept of Obstetrics and Gynecology   (South Korea)

Author keywords

Fugitive acromegaly; IGF 1; Pituitary tumor producing GH and PRL

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C; TESTOSTERONE;

ACROMEGALY; ADULT; ARTICLE; CASE REPORT; CAVERNOUS SINUS; CELL TYPE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS TUMOR; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTERNAL CAROTID ARTERY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; ORAL GLUCOSE TOLERANCE TEST; PATIENT REFERRAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; TESTOSTERONE BLOOD LEVEL; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; VISUAL DISORDER;

EID: 77951077938     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-010-9341-5     Document Type: Article

References (21)

1. P Chanson S Salenave 2008 Acromegaly Orphanet J. Rare Dis. 3 17 10.1186/1750-1172-3-17 18578866
2. A Avramidis SA Polyzos Z Efstathiadou M Kita 2008 Sustained clinical inactivity and stabilization of GH/IGF-1 levels in an acromegalic patient after discontinuation of somatostatin analogue treatment Endocr. J. 55 2 351 357 10.1507/endocrj.K07E-055 1:CAS:528:DC%2BD1cXos1ylsbY%3D 18379126 (Pubitemid 351670962)
3. E Horvath K Kovacs W Singer HS Smyth DW Killinger C Erzin MH Weiss 1981 Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases Cancer 47 4 761 771 10.1002/1097-0142(19810215)47:4<761::AID- CNCR2820470422>3.0.CO;2-L 1:STN:280:DyaL3M7osF2jsQ%3D%3D 6261917 (Pubitemid 11135875)
4. W Saeger DK Ludecke M Buchfelder R Fahlbusch HJ Quabbe S Petersenn 2007 Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry Eur. J. Endocrinol. 156 2 203 216 10.1530/eje.1.02326 1:CAS:528:DC%2BD2sXntlyqu7g%3D 17287410 (Pubitemid 46554515)
5. HG Maheshwari TR Prezant V Herman-Bonert H Shahinian K Kovacs S Melmed 2000 Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma J. Clin. Endocrinol. Metab. 85 9 3409 3416 10.1210/jc.85.9.3409 1:CAS:528:DC%2BD3cXmsVKqtrs%3D 10999842
6. SL Asa K Kovacs E Horvath W Singer HS Smyth 1992 Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophil cell line J. Clin. Endocrinol. Metab. 75 1 68 75 10.1210/jc.75.1.68 1:STN:280:DyaK38zhslegsg%3D%3D 1352308
7. ME Molitch 2003 Dopamine resistance of prolactinomas Pituitary 6 1 19 27 10.1023/A:1026225625897 1:CAS:528:DC%2BD3sXotlajs74%3D 14674720 (Pubitemid 37455641)
8. G Mohr ZP Chen M Schweitzer 1997 Acromegaly with normal basal growth hormone levels Can. J. Neurol. Sci. 24 3 250 253 1:STN:280:DyaK2svit1ShtA%3D%3D 9276113
9. B Swearingen FG Barker 2nd L Katznelson BM Biller S Grinspoon A Klibanski N Moayeri PM Black NT Zervas 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly J. Clin. Endocrinol. Metab. 83 10 3419 3426 10.1210/jc.83.10.3419 1:CAS:528:DyaK1cXmsFKlsrk%3D 9768641 (Pubitemid 28500866)
10. DR Clemmons JJ Van Wyk EC Ridgway B Kliman RN Kjellberg LE Underwood 1979 Evaluation of acromegaly by radioimmunoassay of somatomedin-C N. Engl. J. Med. 301 21 1138 1142 10.1056/NEJM197911223012102 1:CAS:528:DyaL3cXjvFamsA%3D%3D 492275
11. A Colao R Pivonello RS Auriemma MC De Martino M Bidlingmaier F Briganti F Tortora P Burman IA Kourides CJ Strasburger G Lombardi 2006 Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance Eur. J. Endocrinol. 154 3 467 477 10.1530/eje.1.02112 1:CAS:528:DC%2BD28Xjt1Shtbk%3D 16498061
12. CE Higham TT Chung J Lawrance WM Drake PJ Trainer 2009 Long-term experience of pegvisomant therapy as a treatment for acromegaly Clin Endocrinol (Oxf) 71 1 86 91 10.1111/j.1365-2265.2008.03469.x 1:CAS:528:DC%2BD1MXosl2js78%3D
13. M Gradiser M Matovinovic M Vrkljan 2007 Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly Croat. Med. J. 48 1 87 91 17309144
14. AP Heaney M Fernando S Melmed 2003 PPAR-gamma receptor ligands: novel therapy for pituitary adenomas J. Clin. Invest. 111 9 1381 1388 1:CAS:528:DC%2BD3sXjsFCrs74%3D 12727930
15. GJ Kaptain NE Simmons TD Alden MB Lopes ML Vance ER Laws 1999 Estrogen receptors in prolactinomas: a clinico-pathological study Pituitary 1 2 91 98 10.1023/A:1009903603495 1:STN:280:DC%2BD3M%2FlsF2gtA%3D%3D 11081186
16. SW Lamberts LJ Hofland 2009 Future treatment strategies of aggressive pituitary tumors Pituitary 12 3 261 264 10.1007/s11102-008-0154-y 19003539
17. B Caronti G Palladini MG Bevilacqua E Petrangeli B Fraioli G Cantore G Tamburrano CM Carapella ML Jaffrain-Rea 1993 Effects of 17 beta-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: correlation with specific cellular receptors Tumour Biol. 14 1 59 68 10.1159/000217826 1:STN:280:DyaK3s3mt1ensA%3D%3D 8493452
18. I Vourliotaki IE Bonapart C Stamataki EM Tsapakis C Saridaki 2005 A case of a prolactinoma resistant to dopamine agonists Hormones (Athens) 4 3 165 170
19. G Vlotides E Siegel I Donangelo S Gutman SG Ren S Melmed 2008 Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands Cancer Res. 68 15 6377 6386 10.1158/0008-5472.CAN-08-0508 1:CAS:528: DC%2BD1cXpt1Wjtrk%3D 18676863
20. E Gutteridge A Agrawal R Nicholson KL Cheung J Robertson J Gee 2010 The effects of gefitinib in tamoxifen resistant and hormone insensitive breast cancer: a phase II study Int. J. Cancer. 126 8 1806 1816 1:CAS:528: DC%2BC3cXisVahs74%3D 19739079
21. K Kageyama T Nigawara Y Kamata T Takahashi J Anzai S Suzuki YR Osamura T Suda 2002 A case of macroprolactinoma with subclinical growth hormone production Endocr. J. 49 1 41 47 10.1507/endocrj.49.41 12008749